Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab-IRDye 800CW for hilar cholangiocarcinoma detection
NCT03620292Phase 2Unknown
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2019
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in hilar cholangiocarcinoma (HC), sponsored by University Medical Center Groningen. Primary endpoint: Optimal dose finding of Bevacizumab 800CW in hilar cholangiocarcinoma at 24 months. Status: unknown.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on NCT03620292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620292.